Logo image of LMND

LEMONADE INC (LMND) Stock Fundamental Analysis

NYSE:LMND - New York Stock Exchange, Inc. - US52567D1072 - Common Stock - Currency: USD

35.85  +0.76 (+2.17%)

After market: 35.87 +0.02 (+0.06%)

Fundamental Rating

2

Taking everything into account, LMND scores 2 out of 10 in our fundamental rating. LMND was compared to 142 industry peers in the Insurance industry. LMND has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, LMND is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LMND had negative earnings in the past year.
In the past year LMND has reported a negative cash flow from operations.
LMND had negative earnings in each of the past 5 years.
In the past 5 years LMND always reported negative operating cash flow.
LMND Yearly Net Income VS EBIT VS OCF VS FCFLMND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

LMND has a Return On Assets of -11.70%. This is amonst the worse of the industry: LMND underperforms 93.66% of its industry peers.
With a Return On Equity value of -39.84%, LMND is not doing good in the industry: 92.25% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -11.7%
ROE -39.84%
ROIC N/A
ROA(3y)-14.35%
ROA(5y)-14.76%
ROE(3y)-33.95%
ROE(5y)-29.77%
ROIC(3y)N/A
ROIC(5y)N/A
LMND Yearly ROA, ROE, ROICLMND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

LMND does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LMND Yearly Profit, Operating, Gross MarginsLMND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

2

2. Health

2.1 Basic Checks

LMND does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LMND has been increased compared to 1 year ago.
LMND has more shares outstanding than it did 5 years ago.
LMND has a worse debt/assets ratio than last year.
LMND Yearly Shares OutstandingLMND Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
LMND Yearly Total Debt VS Total AssetsLMND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

LMND has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of LMND (0.19) is better than 72.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC9.08%
LMND Yearly LT Debt VS Equity VS FCFLMND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

LMND has a Current Ratio of 0.09. This is a bad value and indicates that LMND is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.09, LMND is in the better half of the industry, outperforming 64.79% of the companies in the same industry.
A Quick Ratio of 0.09 indicates that LMND may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.09, LMND is in the better half of the industry, outperforming 64.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.09
Quick Ratio 0.09
LMND Yearly Current Assets VS Current LiabilitesLMND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

LMND shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.88%.
The Revenue has grown by 23.12% in the past year. This is a very strong growth!
The Revenue has been growing by 50.90% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)2.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.36%
Revenue 1Y (TTM)23.12%
Revenue growth 3Y60.06%
Revenue growth 5Y50.9%
Sales Q2Q%26.95%

3.2 Future

The Earnings Per Share is expected to grow by 17.17% on average over the next years. This is quite good.
LMND is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.67% yearly.
EPS Next Y0.49%
EPS Next 2Y14.15%
EPS Next 3Y17.17%
EPS Next 5YN/A
Revenue Next Year27.53%
Revenue Next 2Y29.33%
Revenue Next 3Y29.9%
Revenue Next 5Y26.67%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
LMND Yearly Revenue VS EstimatesLMND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 500M 1B 1.5B 2B 2.5B
LMND Yearly EPS VS EstimatesLMND Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LMND. In the last year negative earnings were reported.
Also next year LMND is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LMND Price Earnings VS Forward Price EarningsLMND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LMND Per share dataLMND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

LMND's earnings are expected to grow with 17.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.15%
EPS Next 3Y17.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LMND!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEMONADE INC

NYSE:LMND (6/4/2025, 8:04:00 PM)

After market: 35.87 +0.02 (+0.06%)

35.85

+0.76 (+2.17%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupInsurance
GICS IndustryInsurance
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)07-28 2025-07-28/amc
Inst Owners47.37%
Inst Owner Change-0.93%
Ins Owners7.59%
Ins Owner Change-41.62%
Market Cap2.63B
Analysts48
Price Target30.75 (-14.23%)
Short Float %28.92%
Short Ratio9.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.22%
Min EPS beat(2)10.83%
Max EPS beat(2)31.6%
EPS beat(4)4
Avg EPS beat(4)15.32%
Min EPS beat(4)9.28%
Max EPS beat(4)31.6%
EPS beat(8)8
Avg EPS beat(8)14.97%
EPS beat(12)11
Avg EPS beat(12)14.79%
EPS beat(16)15
Avg EPS beat(16)13.28%
Revenue beat(2)2
Avg Revenue beat(2)1.37%
Min Revenue beat(2)0.66%
Max Revenue beat(2)2.09%
Revenue beat(4)3
Avg Revenue beat(4)1.16%
Min Revenue beat(4)-1.78%
Max Revenue beat(4)3.68%
Revenue beat(8)7
Avg Revenue beat(8)2.59%
Revenue beat(12)11
Avg Revenue beat(12)4.36%
Revenue beat(16)15
Avg Revenue beat(16)3.93%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-3.18%
EPS NQ rev (3m)-1.4%
EPS NY rev (1m)0.97%
EPS NY rev (3m)-2.9%
Revenue NQ rev (1m)1.34%
Revenue NQ rev (3m)1.27%
Revenue NY rev (1m)1.24%
Revenue NY rev (3m)0.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.7
P/FCF N/A
P/OCF N/A
P/B 4.82
P/tB 5.1
EV/EBITDA N/A
EPS(TTM)-3.04
EYN/A
EPS(NY)-1.99
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS7.62
BVpS7.45
TBVpS7.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.7%
ROE -39.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.35%
ROA(5y)-14.76%
ROE(3y)-33.95%
ROE(5y)-29.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 47.18%
Cap/Sales 1.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.09
Quick Ratio 0.09
Altman-Z N/A
F-Score4
WACC9.08%
ROIC/WACCN/A
Cap/Depr(3y)58.6%
Cap/Depr(5y)137.73%
Cap/Sales(3y)2.62%
Cap/Sales(5y)3.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.36%
EPS Next Y0.49%
EPS Next 2Y14.15%
EPS Next 3Y17.17%
EPS Next 5YN/A
Revenue 1Y (TTM)23.12%
Revenue growth 3Y60.06%
Revenue growth 5Y50.9%
Sales Q2Q%26.95%
Revenue Next Year27.53%
Revenue Next 2Y29.33%
Revenue Next 3Y29.9%
Revenue Next 5Y26.67%
EBIT growth 1Y-4.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.09%
EBIT Next 3Y26.52%
EBIT Next 5Y25.64%
FCF growth 1Y78.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y83.05%
OCF growth 3YN/A
OCF growth 5YN/A